| P2093 | author name string | Patricia A Kruk | |
| | Kamisha T Woolery | |
| P2860 | cites work | Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation | Q24646390 |
| | Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer | Q72999875 |
| | Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer | Q73047864 |
| | Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma | Q73147564 |
| | Treatment of recurrent ovarian cancer: increasing options--"recurrent" results | Q73443063 |
| | Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer | Q73443071 |
| | Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel | Q73591041 |
| | Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas | Q74201967 |
| | Interleukin-1 | Q77454033 |
| | Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer | Q79208963 |
| | C-reactive protein concentrations and subsequent ovarian cancer risk | Q80076486 |
| | Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells | Q81631602 |
| | The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis | Q84558483 |
| | Epithelial-mesenchymal transitions in tumour progression | Q27860487 |
| | Ovarian surface epithelium: biology, endocrinology, and pathology | Q28211321 |
| | Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer | Q28220263 |
| | A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer | Q28332949 |
| | Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium | Q29030494 |
| | Immunological and inflammatory functions of the interleukin-1 family | Q29619669 |
| | Biologic basis for interleukin-1 in disease | Q29619853 |
| | The international comparability of cancer mortality data. Results of an international death certificate study | Q31070936 |
| | Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression | Q33427809 |
| | Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study. | Q33488193 |
| | Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer | Q33492481 |
| | Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study | Q33501657 |
| | Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel | Q33503973 |
| | Why not treat human cancer with interleukin-1 blockade? | Q33833871 |
| | Phase II biomarker trial of a multimarker diagnostic for ovarian cancer | Q33868802 |
| | Cancer statistics, 2000. | Q33895772 |
| | Symptoms of ovarian cancer | Q34086949 |
| | The paradox of pro-inflammatory cytokines in cancer | Q34572401 |
| | Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine | Q34947284 |
| | Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment | Q35165663 |
| | Endometriosis and ovarian cancer: thoughts on shared pathophysiology | Q35177953 |
| | 11beta-hydroxysteroid dehydrogenases, cell proliferation and malignancy | Q35207794 |
| | Surface epithelium of the developing ovary. Possible correlation with ovarian neoplasia | Q36077313 |
| | Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer | Q36080397 |
| | Ovarian cancer, Part II: Treatment | Q36265619 |
| | Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions | Q36418553 |
| | Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers | Q36418915 |
| | Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials | Q36467605 |
| | Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas | Q36615861 |
| | Vascular endothelial growth factor and its relationship to inflammatory mediators | Q36823246 |
| | Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study | Q36836814 |
| | Etiology and pathogenesis of epithelial ovarian cancer | Q37023632 |
| | Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. | Q37080992 |
| | Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective | Q37094004 |
| | E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium | Q37202994 |
| | IL-1, IL-18, and IL-33 families of cytokines | Q37211243 |
| | Current understanding of risk factors for ovarian cancer | Q37551696 |
| | Inflammation: a hidden path to breaking the spell of ovarian cancer | Q37593899 |
| | Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management | Q37621318 |
| | Epithelial-mesenchymal transition in ovarian cancer. | Q37625486 |
| | Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome | Q37759442 |
| | New insights into pattern recognition receptors and their ligands in gynecologic pathologies | Q37822002 |
| | Steroid signalling in human ovarian surface epithelial cells: the response to interleukin-1alpha determined by microarray analysis. | Q38334694 |
| | The effects of oral contraceptives and parity on ovarian cancer trends in women under 55 years of age. | Q38517080 |
| | An anti-inflammatory role for glucocorticoids in the ovaries? | Q38549469 |
| | "Incessant ovulation" and ovarian cancer | Q39559428 |
| | Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells | Q39726552 |
| | Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions | Q39730578 |
| | TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM [corrected]. | Q39800567 |
| | Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer | Q39813928 |
| | Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population | Q39836194 |
| | Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. | Q40111238 |
| | Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. | Q40160411 |
| | Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions | Q40412257 |
| | Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness | Q40609366 |
| | Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. | Q40665294 |
| | Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer | Q40705982 |
| | The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies | Q40731722 |
| | Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression | Q40968381 |
| | Prospective on ovarian cancer: why prevent? | Q41070247 |
| | Pathology of ovarian cancer precursors | Q41070262 |
| | Epithelial-mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-beta1. | Q41213529 |
| | Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. | Q41437427 |
| | Gemcitabine in ovarian cancer: an overview of safety and efficacy | Q41483397 |
| | Secretion of Bioactive Interleukin-1, Interleukin-6, and Colony-Stimulating Factors by Human Ovarian Surface Epithelium1 | Q41532316 |
| | IL-6 and APPs: anti-inflammatory and immunosuppressive mediators | Q41591668 |
| | Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures | Q41716249 |
| | Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection | Q42823507 |
| | Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis | Q43824359 |
| | Regulation of 11beta-hydroxysteroid dehydrogenase type 1 gene expression in human ovarian surface epithelial cells by interleukin-1. | Q44119044 |
| | Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer | Q44894157 |
| | Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro | Q45135101 |
| | Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. | Q45758228 |
| | Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. | Q45976411 |
| | Interleukin-1 production by transformed fibroblasts. II. Influence on antigen presentation and T-cell-mediated anti-tumor response | Q46517515 |
| | Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells. | Q52951378 |
| | BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. | Q53337299 |
| | Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. | Q54196081 |
| | p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. | Q54520275 |
| | IL-1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma | Q56943710 |
| | Aspirin and ovarian cancer: An Italian case-control study | Q57560716 |
| | Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer | Q57562304 |
| | Constitutive Production of Macrophage Colony-Stimulating Factor and Interleukin-6 by Human Ovarian Surface Epithelial Cells | Q63446369 |
| | Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix | Q67586479 |
| | Ovarian Surface Epithelium: Autonomous Production of Connective Tissue-Type Extracellular Matrix1 | Q67691070 |
| | Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer | Q68150676 |
| | Risk factor for ovarian cancer | Q69157804 |
| | Re: "Familial ovarian cancer: a population-based case-control study" | Q69801383 |
| | Hereditary ovarian cancer. Heterogeneity in age at onset | Q70530649 |
| | High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer | Q70689229 |
| | IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells | Q70948222 |
| | Reciprocal Interactions between Human Ovarian Surface Epithelial Cells and Adjacent Extracellular Matrix | Q71655942 |
| | Interleukin-6 Production by Rat Granulosa Cells in Vitro: Effects of Cytokines, Follicle-Stimulating Hormone, and Cyclic 3′,5′-Adenosine Monophosphate | Q72073429 |
| | Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts | Q72503242 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 358493 | |
| P577 | publication date | 2011-06-26 | |
| P1433 | published in | Obstetrics and gynecology international | Q26842470 |
| P1476 | title | Ovarian epithelial-stromal interactions: role of interleukins 1 and 6. | |
| P478 | volume | 2011 | |